Nuciferine (6) ameliorates NAFLD by reducing necroinflammation (IL-1β, IL-6 and TNF-α) and reversing serum markers of MS (TC, TG and LDL-c) (Cui et al., 2020). Here, IL1B is linked to metabolic dysfunction-associated steatotic liver disease.